Recent advances and emerging therapies in the management of dyslipidemia

Author(s): Andrew Hsieh, Mary R. Dicklin, Michael H. Davidson

Dyslipidemia is a critical risk factor for atherosclerotic cardiovascular disease. Managing dyslipidemia through traditional lifestyle modifications is inadequate for many patients. Statins, the first-line pharmacological therapy, are effective, but are not always tolerated, do not target all types of dyslipidemia, and may not provide sufficient lipid lowering to achieve therapeutic objectives. Thus, novel therapeutic agents that are efficacious, safe, and well tolerated are warranted. This article provides a brief overview of several new and emerging therapies for the management of dyslipidemia including those targeting proprotein convertase subtilisin/kexin type 9, angiopoietin-like protein 3, apolipoprotein C-III, lipoprotein(a), adenosine triphosphate citrate lyase, and cholesteryl ester transfer protein (CETP), through traditional and new vehicle delivery systems, using recent advances in technology, i.e., monoclonal antibody and RNA interference. Growing evidence in support of the CETP inhibitor obicetrapib, an oral, once-daily investigational agent for managing dyslipidemia, suggests that it may be the first-in-class CETP inhibitor available for clinical use.

View PDF View Fulltext